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ABSTRACT 
Here we show that increased plasma SOD1 level significantly predicts therapeutic failure to 
pentavalent antimony in cutaneous leishmaniasis caused by Leishmania braziliensis. In 
Leishmania amazonensis-infected patients, host SOD1 levels discriminate between 
localized and drug-resistant diffuse cutaneous leishmaniasis. Using in situ transcriptomics 
(nCounter), we demonstrate a significant positive correlation between host SOD1 and IFN-
alpha/beta mRNAs, as well as interkingdom correlation between host SOD1 and parasite 
SOD2/4 mRNAs. In human macrophages, SOD1 in vitro treatment increases parasite 
burden and induces diffuse cutaneous leishmaniasis-like morphology. Thus, SOD1 is a 
clinically relevant biomarker and a therapeutic target in both localized and diffuse 
cutaneous leishmaniasis. 
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INTRODUCTION 
Leishmaniasis is endemic in several parts of the world, with a global prevalence of over 12 
million cases. Mainly classified in two distinct clinical forms, leishmaniasis can affect the 
skin (cutaneous leishmaniasis-CL) or viscera (visceral leishmaniasis-VL). Cutaneous 
leishmaniasis, with 1.5 to 2 million new cases per year, is an emerging infectious disease in 
several countries, due to behavioral and environmental changes, as well as HIV co-
infection (1). The clinical spectrum of CL, ranges from the mild cutaneous form (localized 
cutaneous leishmaniasis; LCL) to the disfiguring diffuse cutaneous leishmaniasis (DCL) 
and mucosal form (mucocutaneous leishmaniasis; MCL). Leishmania (L.) braziliensis 
causes LCL and MCL, whereas L. amazonensis causes LCL and, sporadically, DCL (2-4). A 
low parasite load and a variable tendency for self-healing characterize LCL, but treatment 
is strongly recommended to reduce scarring and prevent progression to severe MCL. 
Pentavalent antimonials (SbV) are currently the first-line treatment for LCL, nonetheless, 
24.4% of the treated patients fail to cure with a single cycle of SbV and a second or more 
cycles are indicated to heal the lesions (5). On the other hand, multiple non-ulcerative 
nodules with extremely high parasite burden, as well as a non-healing or relapsing 
phenotype, characterize DCL patients (1, 3, 4, 5). DCL is typically refractory to SbV and 
second-line treatment. Recently, miltefosine treatment induced clinical improvement and 
reduced parasite burden in a cohort of DCL patients, nevertheless treatment suspension lead 
to relapse (6).  
As an obligatory intramacrophage parasite, Leishmania spp. developed several evasion 
mechanisms to avoid human macrophage leishmanicidal activity. One of such mechanisms 
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may involve superoxide dismutase (SOD), a conserved isoenzyme responsible for 
detoxifying reactive superoxide both in Leishmania and human organisms. Previous studies 
have demonstrated that SOD-deficient New World Leishmania species as well as Old 
World Leishmania have enhanced sensitivity to exogenous superoxide in axenic culture and 
reduced survival in mouse and human macrophages (7, 8). We have previously shown an 
IFN-beta-induced SOD1-mediated inhibition of superoxide-dependent parasite killing in 
Leishmania-infected human macrophages in vitro (9). In addition, CL patients have 
increased SOD activity in plasma as compared to normal subjects (10). We hypothesized 
that plasma levels of host SOD1 might reflect clinical status in CL, and might therefore 
represent a candidate biomarker.  
Patients and Methods  
This study was approved by the Ethics Committee of the Gonçalo Moniz Research Center. 
Informed consent was obtained from all patients and healthy controls. Cutaneous 
leishmaniasis patients were diagnosed as described (11), according to characteristic lesion 
morphology, positive skin test, seropositivity towards Leishmania antigen and/or the 
presence of parasites in the lesion. LCL patients infected with Leishmania braziliensis 
(n=58, 27 male, 29.6±2.3 years) were recruited and treated in two outpatient clinics (Jequié 
and Jiquiriçá-BA, NE Brazil) covering the same rural area. LCL patients infected with L 
amazonensis (n=10, 6 male, 38.8±6 years) were recruited and treated at the Professor Edgar 
Santos University Hospital (Salvador-BA, NE Brazil). Plasma samples from LCL patients 
were collected at diagnosis (before treatment). In addition, a paired sample was obtained 
from 13 patients at the time of definite clinical cure (range 68-417 days). LCL patients 
(both L. braziliensis- and L. amazonensis-infected) received standard intravenous 
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pentavalent antimony (Glucantime; Rhodia, 20 mg/kg/day for 20 days). Cure was defined 
by the complete scarring of lesions, without induration and without relapse during two 
years of follow-up. Although all L. amazonensis patients cured within 90 days following a 
single treatment cycle, L.braziliensis patients needed 190.5 ± 16.0 days and 2.2 ± 0.2 
treatment cycles to cure, with 23/58 patients (39.7 %) classified as failing (>2 cycles). DCL 
patients (n=8, 3 male, 31.5 ±7.1 years) infected with L. amazonensis were recruited and 
treated at the Presidente Dutra University Hospital- HUPD (São Luís-MA, NE Brazil). 
DCL patients had mean disease duration of 10.9 ±2.1 years, during which several 
therapeutic schemes (mean of 2.7±0.9 different schemes/patient, including liposomal 
amphotericin B and combinations of Glucantime, IFN-γ and Pentamidine) were applied, 
either without or with only a transient clinical effect. Since DCL is a rare clinical 
manifestation, no samples from untreated patients (at diagnosis) were available for 
comparison. SOD1 plasma levels were quantified using a human SOD1 ELISA Kit 
(Calbiochem). RNA was extracted from skin biopsies of LCL and DCL lesions, as well as 
healthy controls, using Trizol, followed by an additional purification using RNeasy 
(QIAgen Benelux B.V., Venlo, the Netherlands). Using in situ transcriptomics, we 
simultaneously quantified host and parasite RNAs in skin biopsies from LCL and DCL 
patients, as well as healthy controls, by nCounter technology (NanoString, Seattle), based 
on molecular bar-coding of target RNA transcripts and digital detection at the femtomolar 
range using direct hybridization, without reverse transcription nor amplification (12). 
Human SOD1, SOD2, SOD3, IFNA1, IFNA2, IFNA4, IFNB1 and Leishmania braziliensis 
and amazonensis SOD1-5 mRNAs were quantified in situ, in addition to several 
housekeeping genes for normalization (GUSB, G6PD, GAPDH, HPRT1), as well as 
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leukocyte-specific genes (CD3, CD14, CD19, CD56, CD45). Quantification of parasite 
burden in vitro was carried out as described (9). Briefly, monocyte-derived human 
macrophages were infected with L. amazonensis (MHOM/BR/87/BA125) and treated with 
SOD1 (Sigma) for 48h, followed by extensive washing, staining with hematoxylin/eosin 
and counting of intracellular amastigotes (100 cells, duplicates for each sample). Parametric 
and non-parametric tests were used according to Kolmogorov-Smirnov test for normality. 
For multiple comparisons, Kruskal-Wallis with Dunn’s post-test  One-way ANOVA with 
post-test for linear trend were used. For comparison between two group , F-test, Mann 
Whitney, t test or Wilcoxon tests were used. To identify biomarkers, Receiver Operating 
Characteristic (ROC) curve was used. All tests were two-tailed and differences were 
considered significant at P values <0.05.  
Results 
We measured plasma levels of SOD1 in healthy controls, LCL patients (L. braziliensis or L. 
amazonensis-infected patients) and DCL patients (all infected with L. amazonensis) and 
investigated its potential role as a biomarker. SOD1 level increased three-fold from 30.2± 
3.9 pg/ml in healthy controls to 90.6±8.0 pg/ml in LCL patients infected with L. 
braziliensis, (Kruskal-Wallis p<0.01, Dunn’s post-test p<0.001<0.0001), and 3.1 fold to 
93.1±24.7 pg/ml in LCL patients infected with L. amazonensis (Kruskal-Wallis p<0.01, 
Dunn’s post-test p<0.01). On the other hand, SOD1 levels were further increased 4.4 fold 
from 93.1±24.7 pg/ml in LCL patients infected with L. amazonensis) to 407.3±88.0 pg/ml 
in DCL patients, (Mann-Whitney test, p=0.0005) (Fig. 1A). To investigate whether 
increased SOD1 in LCL is related to active disease, SOD1 was also measured in paired 
samples of LCL (L. braziliensis) patients (n=13), at pre-treatment (diagnosis) and post-
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treatment (definite clinical cure). SOD1 levels decreased 1.6 fold from 99.2±20.81 pg/ml to 
60.4±5.2 pg/ml in in pre- vs. post-treatment samples (Wilcoxon matched pairs test, 
p=0.027, Supplementary Figure 1A). Since variances differed significantly between 
controls and LCL patients infected with L. braziliensis, (F-test, p<0.0001), we hypothesized 
that heterogeneous SOD1 levels in LCL patients might reflect differences in clinical status 
and/or therapeutic response. SOD1 levels did not significantly correlate with age, gender, 
disease duration, lesion size or healing time of LCL patients (data not shown). However, 
SOD1 plasma levels were significantly associated with therapeutic response, quantified as 
number of treatment cycles (Kruskal-Wallis p=0.0069, Dunn’s post-test p<0.001, Fig. 1C). 
Using Receiver Operating Characteristic (ROC) curve analysis, successful (1 cycle) and 
failing (>2 cycles) therapeutic response could be significantly discriminated through SOD1 
plasma levels (ROC AUC 0.83, p=0.00025), authenticating its clinical utility as a 
biomarker (Fig. 1D). Above a cut-off of 122 pg/ml, 9 out of 22 failing patients (40.9 %) 
could be identified with 100% specificity, i.e. none of the patients cured with 1 treatment 
cycle displayed SOD1 levels above 122 pg/ml. Strikingly, at a similar cut-off of 112 pg/ml, 
DCL patients could be discriminated from treatable LCL patients (L. amazonensis) with 
100% sensitivity and 90% specificity (ROC AUC 0.95, p=0.001; Fig. 1B).  
To test the hypothesis whether these high levels of SOD1 in plasma of CL patients might be 
directly related to increased parasite burden, human macrophages from healthy donors were 
infected with L. amazonensis (5:1) and cultivated in the absence or presence of recombinant 
SOD1 protein. As shown in Fig. 2A, SOD1 treatment significantly increased parasite load 
(t test, p=0.042). Moreover, infected human macrophages treated with recombinant SOD1 
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protein presented cytomorphological features (Fig. 2B) strikingly similar to the vacuolized 
and highly parasitized macrophages from cutaneous lesions of DCL patients (Fig. 2C).  
Finally, using in situ transcriptomics (nCounter), we demonstrate a significant positive 
correlation between host SOD1 mRNA level and parasite SOD2 (p=0.019, r=0.98) and 
SOD4 (p=0.0026, r=0.99) mRNA in diffuse leishmaniasis. Taken together, these data 
suggest that systemic SOD1 might play a causal role in both the clinical and anatomo-
pathological phenotype of DCL. 
 
Discussion  
Up to now, no non-invasive biomarker for therapeutic response to SbV has been described 
in cutaneous leishmaniasis. In the present work, we demonstrate host SOD1 as a biomarker 
for therapeutic failure of first-line SbV in New World CL patients. SOD1 plasma levels 
could significantly discriminate between successful and failing therapeutic response in LCL 
patients (L. braziliensis) and between treatable LCL patients (L. amazonensis) and 
refractory DCL patients. Quantification of SOD1 plasma level at diagnosis represents a 
rapid, sensitive and inexpensive new tool in the clinical management of CL. Further 
research will be necessary to test its predictive value in CL caused by other Leishmania 
species, since in Peru therapeutic failure to antimonial therapy is significantly associated 
with L.braziliensis and L. peruviana, but not with L. guyanensis (5). By identifying, at the 
time of diagnosis, up to 38.5 % of patients (with 100% specificity) who will fail antimonial 
therapy (Fig.1C), second-line treatment (e.g. amphotericin B, miltefosine) could be 
provided as a first choice, thereby diminishing public health costs and avoiding 
 at Biom
edical library on February 10, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
9 
unnecessary and prolonged exposure of the patients to the often severe side effects of 
intravenous pentavalent antimony. 
Although SOD1 is an intracellular antioxidant enzyme, our results suggest a direct role for 
increased systemic (plasma) SOD1, as a trigger of parasite replication in infected 
macrophages. Likewise, treatment of infected human macrophages with purified SOD1 in 
vitro lead to strongly increased parasite burden and the appearance of large parasitophorous 
vacuoles, reminiscent of typical nodular lesions in diffuse leishmaniasis (13). Moreover, 
this correlation between SOD1 and parasite burden was recapitulated in situ in DCL 
lesions, as evidenced by a strong linear relationship (r=098-0.99) between host (human 
SOD1) and parasite (L. amazonensis SOD2 and SOD4) superoxide dismutases. This 
parallel cross-regulation at the transcriptional level between superoxide-quenching enzymes 
that are hundreds of million years distant in evolution is a striking example of interkingdom 
signaling. To our knowledge, this is the first description of interkingdom signaling in 
protozoan-animal interaction. In keeping with our cytomorphological data (Fig. 2B), this 
phenomenon is highly specific for cytosolic SOD1, since cross-kingdom correlations were 
not observed for mitochondrial SOD2 or extracellular SOD3 with any of the parasite 
mRNAs. The extremely long (mean disease duration of 10.9 ±2.1 years) uncontrolled 
parasite replication in DCL patients might have lead to selection of SOD-overexpressing 
parasite clones (7, 8). Alternatively, increased systemic levels of SOD1 in LCL and DCL 
patients might reflect a parasite escape mechanism from host leishmanicidal activity 
mediated by type I IFN, as suggested by our previous work (9) and recently confirmed in 
murine and human macrophages (14). In agreement with this hypothesis, we found a 
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significant positive correlation between SOD1 mRNA and total IFN-alpha/beta mRNA 
levels using in situ transcriptomics (nCounter, Supplementary Figure 2A).  
Finally, since all our DCL patients also failed multiple other treatment schemes (including 
pentamidine, amphotericin B and IFN-gamma, alone or in combination), increased plasma 
SOD1 truly reflects broad therapeutic failure. The dramatic increase in DCL also reinforces 
the idea that SOD1 is not a mere ‘surrogate’ marker, but a key molecule in DCL 
pathogenesis, driving perennial parasite replication and systemic dissemination, as 
suggested by Fig. 2A-D. Hence, SOD1 is also a candidate therapeutic target in CL, 
reinforcing our previous suggestion of pharmacologic SOD1 inhibition by DETC (15) as a 
viable therapeutic alternative in LCL and DCL in particular, for which no effective 
treatment options exist. 
In conclusion, our results indicate host SOD1 as a clinically useful biomarker for 
therapeutic failure, as well as a possible therapeutic target, in localized and diffuse 
cutaneous leishmaniasis.  
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Figure Legends 
 
Figure 1: SOD1 is a biomarker for therapeutic failure in cutaneous leishmaniasis. (A) 
SOD1 measurements in plasma samples of healthy controls (n=20), LCL patients (L. 
braziliensis) (n=58), LCL patients (L. amazonensis) (n=10) and DCL patients (L. 
amazonensis) (n=8). Box-whiskers plots represent the median and interquartile range of 
each group (Kruskal-Wallis test p<0.001, Dunn's post-test, healthy controls vs. LCL 
patients (L. braziliensis) ***p<0.001, healthy controls vs. LCL patients (L. amazonensis) 
**p<0.01, and Mann Whitney test, LCL patients (L. amazonensis) vs. DCL ***p<0.001). 
(B) Plasma SOD1 level significantly discriminates LCL from DCL patients (all infected by 
L. amazonensis, ROC AUC 0.95, ***p=0.001). (C) SOD1 measurements in plasma samples 
of LCL patients (L. braziliensis) classified according to number of treatment cycles 
(Kruskal-Wallis p=0.0069, Dunn’s post-test **p<0.001), three outliers (Tukey’s test) are 
shown as single dots. (D) Plasma SOD1 level significantly predicts therapeutic response in 
LCL patients (L. braziliensis) (Success =1 treatment cycle, Failure >2 treatment cycles) 
(ROC AUC 0.83, ***p=0.00025, without outliers as in (C)). 
Figure 2: SOD1 correlates to parasite burden in vitro and in situ in DCL. (A) and (B) 
Human macrophages were infected with Leishmania amazonensis (5:1 ratio) for 4h and 
then treated in the absence or presence of SOD1 (175 U/ml) protein for 48h. Cells were 
fixed on glass slides and stained with hematoxylin and eosin. (A) Parasite burden was 
quantified, each bar represents the mean ± SEM of 3 donors (t test, *p=0.042). (B) Infected 
macrophages (1000x magnification) left untreated (left panel) or SOD1-treated (right 
panel). (C) Cutaneous lesion biopsy of a representative DCL patient stained with 
hematoxylin and eosin (1000x magnification). (D) Positive correlation between human 
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SOD1 and parasite SOD2 (Pearson correlation, r=0.98, p=0.019) and SOD4 (Pearson 
correlation, r=0.99, p=0.0026) mRNA levels (normalized to G6PD), quantified by nCounter 
in situ in DCL biopsies (n=4). 
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